A Phase 1 interventional study of Abemaciclib Capsules (Reference Formulation) and Abemaciclib Tablet (Test Formulation) in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-04.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to measure how much abemaciclib gets into the blood stream and how long it takes the body to get rid of it when given as capsules versus a tablet(s). The effect of a high fat meal on the tablet formulation will also be evaluated. In addition, the tolerability of abemaciclib tablet and capsule formulations will be evaluated. Information about any side effects that may occur will also be collected.
This study has 3 parts. Parts A and C will last about 44 days including follow-up. Part B will last about 60 days including follow-up. Screening may occur up to 28 days before the first dose of study drug. Participants are only allowed to enroll in one part.
This study is for research purposes only and is not intended to treat any medical condition.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.
Drug: Abemaciclib Capsules (Reference Formulation) · Drug: Abemaciclib Tablet (Test Formulation)
R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.
Drug: Abemaciclib Capsules (Reference Formulation) · Drug: Abemaciclib Tablet (Test Formulation)
T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.
Drug: Abemaciclib Tablet (Test Formulation)
Administered orally
Also known as: LY2835219
Administered orally
Also known as: LY2835219
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])
Area under the concentration versus time curve from zero to infinity.
Time frame: Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose
PK: Maximum Observed Drug Concentration (Cmax)
Maximum observed drug concentration.
Time frame: Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose
| Milestone | Part A: Abemaciclib (R,T150 ) | Part A: Abemaciclib (T150,R) | Part B: Abemaciclib (R,T150,T50 ) | Part B: Abemaciclib (T150,T50,R) | Part B: Abemaciclib (T50,R,T150) | Part B: Abemaciclib (R,T50,T150) | Part B: Abemaciclib (T150,R,T50) | Part B: Abemaciclib (T50,T150,R) | Part C: Abemaciclib (T150 Fed, T150 Fasted) | Part C: Abemaciclib (T150 Fasted, T150 Fed) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 7 | 14 | 15 | 15 | 15 | 15 | 15 | 12 | 12 |
| Received at least one dose of study drug | 7 | 7 | 14 | 15 | 15 | 15 | 15 | 15 | 12 | 12 |
| Completed | 7 | 7 | 14 | 15 | 14 | 15 | 15 | 15 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Abemaciclib (R,T150 ) | Part A: Abemaciclib (T150,R) | Part B: Abemaciclib (R,T150,T50 ) | Part B: Abemaciclib (T150,T50,R) | Part B: Abemaciclib (T50,R,T150) | Part B: Abemaciclib (R,T50,T150) | Part B: Abemaciclib (T150,R,T50) | Part B: Abemaciclib (T50,T150,R) | Part C: Abemaciclib (T150 Fed, T150 Fasted) | Part C: Abemaciclib (T150 Fasted, T150 Fed) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 7 | 14 | 15 | 14 | 15 | 15 | 15 | 12 | 12 |
| Completed | 7 | 7 | 14 | 15 | 14 | 15 | 15 | 15 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Abemaciclib (R,T150 ) | Part A: Abemaciclib (T150,R) | Part B: Abemaciclib (R,T150,T50 ) | Part B: Abemaciclib (T150,T50,R) | Part B: Abemaciclib (T50,R,T150) | Part B: Abemaciclib (R,T50,T150) | Part B: Abemaciclib (T150,R,T50) | Part B: Abemaciclib (T50,T150,R) | Part C: Abemaciclib (T150 Fed, T150 Fasted) | Part C: Abemaciclib (T150 Fasted, T150 Fed) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 7 | 14 | 15 | 14 | 15 | 15 | 15 | 12 | 12 |
| Completed | 7 | 7 | 13 | 15 | 14 | 15 | 15 | 15 | 12 | 12 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Abemaciclib (R,T150 ) | Part A: Abemaciclib (T150,R) | Part B: Abemaciclib (R,T150,T50 ) | Part B: Abemaciclib (T150,T50,R) | Part B: Abemaciclib (T50,R,T150) | Part B: Abemaciclib (R,T50,T150) | Part B: Abemaciclib (T150,R,T50) | Part B: Abemaciclib (T50,T150,R) | Part C: Abemaciclib (T150 Fed, T150 Fasted) | Part C: Abemaciclib (T150 Fasted, T150 Fed) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 7 | 13 | 15 | 14 | 15 | 15 | 15 | 12 | 12 |
| Completed | 7 | 7 | 13 | 15 | 14 | 15 | 15 | 15 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Abemaciclib (R,T150 ) | Part A: Abemaciclib (T150,R) | Part B: Abemaciclib (R,T150,T50 ) | Part B: Abemaciclib (T150,T50,R) | Part B: Abemaciclib (T50,R,T150) | Part B: Abemaciclib (R,T50,T150) | Part B: Abemaciclib (T150,R,T50) | Part B: Abemaciclib (T50,T150,R) | Part C: Abemaciclib (T150 Fed, T150 Fasted) | Part C: Abemaciclib (T150 Fasted, T150 Fed) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 13 | 15 | 14 | 15 | 15 | 15 | 0 | 0 |
| Completed | 0 | 0 | 13 | 15 | 14 | 14 | 15 | 14 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Area under the concentration versus time curve from zero to infinity.
| Nanograms*hour/milliliter (ng*hr/mL) | Part A: 150 mg Abemaciclib (T150) | Part A: 3 x 50 mg Abemaciclib (R) | Part B: 150 mg Abemaciclib (T150) | Part B: 3 x 50 mg Abemaciclib (T50) | Part B: 3 x 50 mg Abemaciclib (R) | Part C: 150 mg Abemaciclib (Fed) | Part C: 150 mg Abemaciclib (Fasted) |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) | 3080 ± 57 | 2880 ± 56 | 3110 ± 55 | 3120 ± 52 | 3130 ± 59 | 4170 ± 49 | 3590 ± 45 |
Maximum observed drug concentration.
| Nanograms per milliliter (ng/mL) | Part A: 150 mg Abemaciclib (T150) | Part A: 3 x 50 mg Abemaciclib (R) | Part B:150 mg Abemaciclib (T150) | Part B: 3 x 50 mg Abemaciclib (T50) | Part B: 3 x 50 mg Abemaciclib (R) | Part C:150 mg Abemaciclib (Fed) | Part C:150 mg Abemaciclib (Fasted) |
|---|---|---|---|---|---|---|---|
| PK: Maximum Observed Drug Concentration (Cmax) | 104 ± 52 | 101 ± 56 | 95.2 ± 48 | 97.7 ± 50 | 95.8 ± 51 | 130 ± 44 | 99.6 ± 36 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: 3 x 50 mg (R) | — | 0/14 (0%) | 7/14 (50%) |
| Part A: 1 x 150 mg (T150) | — | 0/14 (0%) | 6/14 (42.9%) |
| Part B: 3 x 50 mg (R) | — | 0/88 (0%) | 21/88 (23.9%) |
| Part B 1 x 150 mg (T150) | — | 0/87 (0%) | 17/87 (19.5%) |
| Part B 3 x 50 mg (T50) | — | 0/88 (0%) | 22/88 (25%) |
| Part C: (T150 Fed, T150 Fasted) | — | 0/24 (0%) | 3/24 (12.5%) |
| Part C: (T150 Fasted, T150 Fed) | — | 0/24 (0%) | 1/24 (4.2%) |
| Event | Part A: 3 x 50 mg (R) | Part A: 1 x 150 mg (T150) | Part B: 3 x 50 mg (R) | Part B 1 x 150 mg (T150) | Part B 3 x 50 mg (T50) | Part C: (T150 Fed, T150 Fasted) | Part C: (T150 Fasted, T150 Fed) |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/14 | 4/14 | 8/88 | 9/87 | 12/88 | 3/24 | 0/24 |
| DiarrhoeaGastrointestinal disorders | 2/14 | 1/14 | 4/88 | 5/87 | 5/88 | 0/24 | 1/24 |
| VomitingGastrointestinal disorders | 2/14 | 1/14 | 4/88 | 4/87 | 5/88 | 1/24 | 0/24 |
| FatigueGeneral disorders | 2/14 | 0/14 | 1/88 | 1/87 | 1/88 | 0/24 | 0/24 |
| DizzinessNervous system disorders | 2/14 | 1/14 | 0/88 | 1/87 | 2/88 | 1/24 | 0/24 |
| HeadacheNervous system disorders | 2/14 | 1/14 | 11/88 | 7/87 | 7/88 | 2/24 | 0/24 |
| Abdominal painGastrointestinal disorders | 1/14 | 0/14 | 2/88 | 3/87 | 4/88 | 0/24 | 1/24 |
| ConstipationGastrointestinal disorders | 1/14 | 0/14 | 1/88 | 1/87 | 4/88 | 0/24 | 0/24 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/14 | 1/14 | 1/88 | 0/87 | 1/88 | 0/24 | 0/24 |
| Back painMusculoskeletal and connective tissue disorders | 0/14 | 1/14 | 1/88 | 0/87 | 1/88 | 0/24 | 0/24 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Part A: Abemaciclib | Part B Abemaciclib | Part C Abemaciclib | Total |
|---|---|---|---|---|
| Mean | 53.6 ± 16.9 | 51.8 ± 11.6 | 55.5 ± 10.6 | 52.7 ± 12 |
| Sex: Female, Male(Participants) | Part A: Abemaciclib | Part B Abemaciclib | Part C Abemaciclib | Total |
|---|---|---|---|---|
| Female | 11 | 78 | 21 | 110 |
| Male | 3 | 11 | 3 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Abemaciclib | Part B Abemaciclib | Part C Abemaciclib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 24 | 10 | 38 |
| Not Hispanic or Latino | 10 | 65 | 14 | 89 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A: Abemaciclib | Part B Abemaciclib | Part C Abemaciclib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 13 | 0 | 16 |
| White | 9 | 69 | 22 | 100 |
| More than one race | 2 | 6 | 1 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A: Abemaciclib | Part B Abemaciclib | Part C Abemaciclib | Total |
|---|---|---|---|---|
| United States | 14 | 89 | 24 | 127 |
The record gives a start of Feb 2016, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib